A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Latest Information Update: 07 Nov 2021
At a glance
- Drugs SAN 300 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bausch Health Companies; Salix Pharmaceuticals; Santarus
- 26 Apr 2017 Status changed from recruiting to completed.
- 26 Aug 2014 According to the ClinicalTrials.gov record, planned number of patients changed from 90 to 40.
- 26 Aug 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2015 to 1 Jun 2016.